Form 4: Medicinoiva Inc. Director Carolyn Beaver Acquires Stock Options
SEC Form 4
Director Carolyn Beaver acquired 24,500 stock options in Medicinoiva Inc. on February 12, 2025, exercisable at $1.84, vesting in quarterly installments, and expiring on February 11, 2035.
Summary
- On February 12, 2025, Carolyn Beaver, a director of Medicinoiva Inc., acquired 24,500 stock options.
- The exercise price of these options is $1.84.
- The options vest in four equal installments starting May 12, 2025, and ending February 12, 2026, contingent upon continued service with the company.
- The options expire on February 11, 2035.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. The sentiment is neither particularly positive nor negative.
Positives
- The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are standard practice and provide transparency into insider transactions, which are closely monitored by investors.
Stakeholder Impact
- The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 02/12/2025 | Date of transaction: Carolyn Beaver acquired stock options. |
| 05/12/2025 | First vesting date for the stock options. |
| 08/12/2025 | Second vesting date for the stock options. |
| 11/12/2025 | Third vesting date for the stock options. |
| 02/12/2026 | Fourth vesting date for the stock options. |
| 02/11/2035 | Expiration date of the stock options. |
| 02/14/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.